SB 906 — Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations
Last action — Chapter 249, Acts, Regular Session, 2026
-
✓Introduced
-
✓In Committee
-
✓Passed Senate
-
✓Passed House of Delegates
-
✓To Executive
-
6Enacted
This bill has been enacted into law. Introduced February 10, 2026. Enacted.
Odds of enactment
High chanceBased on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.
Upgrade to see the exact probability and what's driving it.
A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.
Prognosis
-
Enacted
Current position in the legislative process.
-
1 sponsor
1 primary, 0 co-sponsors signed on.
-
Single-party support
Sponsorship is currently within one party (1 R).
-
Cleared a recorded vote
Passed 3 recorded votes so far.
Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.
In plain language
Allows lawful prescription of crystalline polymorph psilocybin under FDA guidelines.
This bill permits the prescription of crystalline polymorph psilocybin, a compound that may be used for medical purposes, following FDA recommendations. It aims to regulate its use properly within the healthcare system.
What this means for you
- Healthcare: This means healthcare providers can legally prescribe psilocybin for therapeutic uses under FDA guidelines.
Summary
Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations
Bill Text
What changed in the latest version
667 added · 1 removedPlain-language change summary
The recent amendment to Senate Bill 906 enables the lawful prescription, distribution, and marketing of a specific form of psilocybin, a substance derived from mushrooms, once it is approved by the Food and Drug Administration (FDA) and rescheduled by the Drug Enforcement Administration (DEA). This change is significant as it establishes a clear legal pathway for this medicinal substance, potentially allowing patients access to new therapeutic options for conditions like depression and anxiety. By streamlining the regulatory process, the amendment also encourages innovation in medicinal treatments within West Virginia.
SB906WEST HFAVIRGINIA BurkhammerLEGISLATURE 3-13REGULAR #2CRSESSION 3338DelegateEnrolled BurkhammerSenate movedBill to906 amendBYSENATORDEEDS Engrossed[Passed SB906March bill,14, as2026; amended, on page 3, line 43, by striking subsection (g) in its entirety and inserting in lieu thereof a new subsection (g) to read as follows:
“(g)in Notwithstandingeffect §60A-2-204(d)90 ofdays thisfrom code,passage if(June a12, drug2026)] thatEnr contains,SB an906 organicAN psilocybinACT substanceto oramend theand pharmaceuticalreenact composition§60A-2-201 and §60A-2-204 of crystallinethe polymorphCode psilocybin,of isWest approvedVirginia, by1931, theas Unitedamended, Statesrelating Foodto andpermitting Drugthe Administrationlawful andprescription, rescheduleddistribution, byand themarketing Unitedof Statesany Drugcomposition Enforcementof Administrationcrystalline itpolymorph shallpsilocybin bethat lawfulthe toUnited prescribe,States distribute,Food and marketDrug basedAdministration uponapproves theand recommendationsthat ofis rescheduled by the United States Food and Drug Administration.” AdoptedRejectedEnforcement Administration.
Be it enacted by the Legislature of West Virginia:
ARTICLE 2.
STANDARDS AND SCHEDULES.
§60A-2-201.
Authority of Board of Pharmacy;
recommendations to Legislature.
(a) The Board of Pharmacy shall administer the provisions of this chapter.
It shall also, on the first day of each regular legislative session, recommend to the Legislature which substances should be added to or deleted from the schedules of controlled substances contained in this article or reschedule therein.
The Board of Pharmacy shall also have the authority between regular legislative sessions, on an emergency basis, to add to or delete from the schedules of controlled substances contained in this article or reschedule such substances based upon the recommendations and approval of the federal food, drug and cosmetic agency, and shall report such actions on the first day of the regular legislative session immediately following said actions.
In making any such recommendation regarding a substance, the Board of Pharmacy shall consider the following factors:
(1) The actual or relative potential for abuse;
(2) The scientific evidence of its pharmacological effect, if known;
(3) The state of current scientific knowledge regarding the substance;
(4) The history and current pattern of abuse;
(5) The scope, duration and significance of abuse;
(6) The potential of the substance to produce psychic or physiological dependence liability;
and Enr SB 906 (7) Whether the substance is an immediate precursor of a substance already controlled under this article.
(b) After considering the factors enumerated in subsection (a) of this section, the Board of Pharmacy shall make findings with respect to the substance under consideration.
If it finds that any substance not already controlled under any schedule has a potential for abuse, it shall recommend to the Legislature that the substance be added to the appropriate schedule.
If it finds that any substance already controlled under any schedule should be rescheduled or deleted, it shall so recommend to the Legislature.
(c) If the Board of Pharmacy designates a substance as an immediate precursor, substances which are precursors of the controlled precursor shall not be subject to control solely because they are precursors of the controlled precursor.
(d) If any substance is designated, rescheduled, or deleted as a controlled substance under federal laws and notice thereof is given to the Board of Pharmacy, the board shall recommend similar control of such substance to the Legislature, specifically stating that such recommendation is based on federal action and the reasons why the federal government deemed such action necessary and proper.
(e) The authority vested in the board by subsection (a) of this section shall not extend to distilled spirits, wine, malt beverages, or tobacco as those terms are defined or used in other chapters of this code nor to any nonnarcotic substance if such substance may under the Federal Food, Drug and Cosmetic Act and the law of this state lawfully be sold over the counter without a prescription.
(f) Notwithstanding any provision of this chapter to the contrary, the sale, wholesale, distribution, or prescribing of a cannabidiol or nabiximols in a product approved by the Food and Drug Administration is permitted and shall be placed on the schedule or descheduled as provided for by the Drug Enforcement Administration.
Enr SB 906 (g) Notwithstanding §60A-2-204(d) of this code, if a drug that contains, an organic psilocybin substance or the pharmaceutical composition of crystalline polymorph psilocybin, is approved by the United States Food and Drug Administration and rescheduled by the United States Drug Enforcement Administration it shall be lawful to prescribe, distribute, and market based upon the recommendations of the United States Food and Drug Administration.
§60A-2-204.
Schedule I.
(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section including their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.
(b) Opiates.
Acetyl-alpha-methylfentanyl(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]- phenylacetamide);
Acetylmethadol;
Allylprodine;
Alphacetylmethadol (except levoalphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM);
Alphameprodine;
Alphamethadol;
Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propionanilide;
1-(1-methyl-2-phenylethyl)-4-(( propanilido) piperidine);
Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]- phenylpropanamide);
Show all 500 changed lines (460 more)
Benzethidine;
Betacetylmethadol;
Enr SB 906 Beta-hydroxyfentanyl(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide);
Beta-hydroxy-3-methylfentanyl (other name:
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4- piperidinyl]-N-phenylpropanamide);
Betameprodine;
Betamethadol;
Betaprodine;
Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol- 2-one);
Clonitazene;
Dextromoramide;
Diampromide;
Diethylthiambutene;
Difenoxin;
Dimenoxadol;
Dimepheptanol;
Dimethylthiambutene;
Dioxaphetyl butyrate;
Dipipanone;
Ethylmethylthiambutene;
Etonitazene;
Etoxeridine;
Fentanyl analog or derivative, as that term is defined in article one of this chapter:
Provided, That fentanyl and carfentanil remains a Schedule II substance, as set forth in §60A-2- 206 of this code;
Furethidine;
Enr SB 906 Hydroxypethidine;
Ketobemidone;
Levomoramide;
Levophenacylmorphan;
3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl) ethyl-4-piperidinyl]-phenylpropanamide);
Morpheridine;
N-Methylnorfentanyl (N-(1-Methyl-4-piperidinyl)-N-phenyl-propanamide, monohydrochloride);
MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
Noracymethadol;
Norlevorphanol;
Normethadone;
Norpipanone;
Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide);
PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
Phenadoxone;
Phenampromide;
Phenomorphan;
Phenoperidine;
Piritramide;
Proheptazine;
Properidine;
Propiram;
Racemoramide;
Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide);
Enr SB 906 Tilidine;
Trimeperidine.
(c) Opium derivatives.
Acetorphine;
Acetyldihydrocodeine;
Benzylmorphine;
Codeine methylbromide;
Codeine-N-Oxide;
Cyprenorphine;
Desomorphine;
Dihydromorphine;
Drotebanol;
Etorphine (except HCl Salt);
Heroin;
Hydromorphinol;
Methyldesorphine;
Methyldihydromorphine;
Morphine methylbromide;
Morphine methylsulfonate;
Morphine-N-Oxide;
Myrophine;
Nicocodeine;
Nicomorphine;
Normorphine;
Pholcodine;
Thebacon.
Enr SB 906 (d) Hallucinogenic substances.
Alpha-ethyltryptamine;
some trade or other names:
etryptamine;
Monase;
alpha-ethy-1H-indole- 3-ethanamine;
3-(2- aminobutyl) indole;
alpha-ET;
and AET;
1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names:
para-methoxymethamphetamine, PMMA);
4-bromo-2, 5-dimethoxy-amphetamine;
some trade or other names:
4-bromo-2,5- dimethoxy-alpha-methylphenethylamine;
4-bromo- 2,5-DMA;
4-Bromo-2,5-dimethoxyphenethylamine;
some trade or other names:
2-(4-bromo-2,5- dimethoxyphenyl)-1-aminoethane;
alpha- desmethyl DOB;
2C-B, Nexus;
N-(2-Methoxybenzyl)-4-bromo-2, 5-dimethoxyphenethylamine.
The substance has the acronym 25B-NBOMe;
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C-NBOMe);
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I-NBOMe);
2,5-dimethoxyamphetamine;
some trade or other names:
2,5-dimethoxy-alpha- methylphenethylamine;
2,5-DMA;
2,5-dimethoxy-4-ethylamphet-amine;
some trade or other names:
DOET;
2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name:
2C-T-7);
4-methoxyamphetamine;
some trade or other names:
4-methoxy-alpha- methylphenethylamine;
paramethoxyamphetamine;
PMA;
3-Hydoxy-phencyclidine (other name hydroxy PCP);
5-methoxy-3, 4-methylenedioxy-amphetamine;
4-methyl-2,5-dimethoxy-amphetamine;
some trade and other names:
4-methyl-2,5- dimethoxy-alpha-methylphenethylamine;
"DOM";
and "STP";
3,4-methylenedioxy amphetamine;
3,4-methylenedioxymethamphetamine (MDMA);
Enr SB 906 3,4-methylenedioxy-N-ethylamphetamine (also known as ( ethyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA, MDE, MDEA);
N-hydroxy-3,4-methylenedioxyamphetamine (also known as ( hydroxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and ( hydroxy MDA);
3,4,5-trimethoxy amphetamine;
5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
Alpha-methyltryptamine (other name:
AMT);
Bufotenine;
some trade and other names:
3-(beta-Dimethylaminoethyl)-5- hydroxyindole;3-(2-dimethylaminoethyl) -5-indolol;
N, N-dimethylserotonin;
5-hydroxy-N,N- dimethyltryptamine;
mappine;
Diethyltryptamine;
sometrade and other names:
N, N-Diethyltryptamine;
DET;
Dimethyltryptamine;
some trade or other names:
DMT;
5-Methoxy-N,N-disopropyltryptamine (5-MeO-DIPT);
Ibogaine;
some trade and other names:
7-Ethyl-6, 6 Beta, 7, 8, 9, 10, 12, 13-octahydro- 2-methoxy-6, 9-methano-5H- pyrido [1’, 2’:
1, 2] azepino [5,4-b] indole;
Tabernanthe iboga;
Lysergic acid diethylamide;
Marihuana;
Marijuana (Cannabis, sp.);
Mescaline;
Parahexyl-7374;
some trade or other names:
3-Hexyl -1-hydroxy-7, 8, 9, 10-tetrahydro- 6, 6, 9-trimethyl-6H-dibenzo [b,d] pyran;
Synhexyl;
Peyote;
meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, immediate derivative, mixture, or preparation of such plant, its seeds or extracts;
N-ethyl-3-piperidyl benzilate;
N-methyl-3-piperidyl benzilate;
Enr SB 906 Psilocybin;
except as provided for in §60A-2-201(g) of this code;
Psilocyn;
Tetrahydrocannabinols;
synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp.
and/or synthetic substances, immediate derivatives and their isomers with similar chemical structure and pharmacological activity including, but not limited to the following:
delta-1 Cis or trans tetrahydrocannabinol, and their optical isomers;
delta-6 Cis or trans tetrahydrocannabinol, and their optical isomers;
delta-3,4 Cis or trans tetrahydrocannabinol, and its optical isomers;
delta-8 Cis or trans tetrahydrocannabinol and its optical isomers;
and delta-10 Cis or trans tetrahydrocannabinol and its optical isomers;
(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.) Delta-8-tetrahydrocannabinol-O (delta-8-THC-0), Delta-9-tetrahydrocannabinol (delta-9- THC-0) and Synthetic and non-naturally occurring cannabinoids.
The provisions of this section related to tetrahydrocannabinols are inapplicable to products or substances lawfully manufactured, distributed, or possessed under the provisions of §19-12E-1 et seq.
and chapter 16H of this code.
Ethylamine analog of phencyclidine;
some trade or other names:
N-ethyl-1- phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
Pyrrolidine analog of phencyclidine;
some trade or other names:
1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP;
Thiophene analog of phencyclidine;
some trade or other names:
1-[1-(2-thienyl)- cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine;
TPCP, TCP;
1[1-(2-thienyl)cyclohexyl]pyrroldine;
some other names:
TCPy;
Enr SB 906 4-methylmethcathinone (Mephedrone);
3,4-methylenedioxypyrovalerone (MDPV);
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P);
3,4-Methylenedioxy-N-methylcathinone (Methylone);
2,5-dimethoxy-4-(n)-propyltghiophenethylamine (2C-T-7, itsoptical isomers, salts and salts of isomers;
5-methoxy-N,N-dimethyltryptamine some trade or other names:
5-methoxy-3-[2- (dimethylamino)ethyl]indole;
5-MeO-DMT(5-MeO-DMT);
Alpha-methyltryptamine (other name:
AMT);
5-methoxy-N,N-diisopropyltryptamine (other name:
5-MeO-DIPT);
Synthetic Cannabinoids as follows:
2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol) { also known as CP 47,497 and homologues} ;
rel-2-[(1S,3R)-3-hydroxycyclohexyl] -5-(2-methylnonan-2-yl)phenol { also known as CP 47,497-C8 homolog} ;
[(6aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a, 7,10,10a- tetrahydrobenzo[c]chromen-1-ol)] { also known as HU-210} ;
(dexanabinol);
Enr SB 906 (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzol[c]chromen-1-ol) { also known as HU-211} ;
1-Pentyl-3-(1-naphthoyl)indole { also known as JWH-018} ;
1-Butyl-3-(1-naphthoyl)indole { also known as JWH-073} ;
(2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-methanone { also known as JWH-015} ;
(1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone { also known as JWH-019} ;
[1-[2-(4-morpholinyl) ethyl] -1H-indol-3-yl]-1-naphthalenyl-methanone { also known as JWH-200} ;
1-(1-pentyl-1H-indol-3-yl)-2-(3-hydroxyphenyl)-ethanone { also known as JWH-250} ;
2-((1S,2S,5S)-5-hydroxy-2-(3-hydroxtpropyl)cyclohe-5-(2-methyloctan-2-yl)phenol {also known as CP 55,940} ;
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl)-methanone { also known as JWH- 122};
(4-methyl-1-naphthalenyl) (1-pentyl-1H-indol-3-yl)-methanone { also known as JWH-398;
(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone { also known as RCS-4} ;
1-(1-(2-cyclohexylethyl) -1H-indol-3-yl) -2-(2-methoxyphenyl) ethanone { also known as RCS-8} ;
1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);
and 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).
Synthetic cannabinoids:
CP 47,497 AND homologues, 2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2- YL)phenol);
HU-210, [(6AR,10AR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-Methyloctan-2-YL)-6A,7,10, 10A-tetrahydrobenzo[C] chromen-1-OL)];
Enr SB 906 HU-211, (dexanabinol, (6AS,10AS)-9-(hydroxymethyl)-6,6-Dimethyl-3-(2-methyloctan-2- YL)-6A,7,10,10atetrahydrobenzo[ C]chromen-1-OL);
JWH-018, 1-pentyl-3-(1-naphthoyl)indole;
JWH-019, 1-hexyl-3-(1-naphthoyl)indole;
JWH-073, 1-butyl-3-(1-naphthoyl)indole;
JWH-200, (1-(2-morpholin-4-ylethyl)indol-3-yl)- Naphthalen-1-ylmethanone;
JWH-250, 1-pentyl-3-(2-methoxyphenylacetyl)indole.] Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylb(5F-oate ADB);
Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F-AMB);
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbuta(FUB- AMB);
N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (5F-APINACA);
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA);
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-CHMICA);
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB-FUBINACA);
Tetrahydrocannabinols:
DELTA-1 CIS OR trans tetrahydrocannabinol and their optical isomers.
DELTA-6 CIS OR trans tetrahydrocannabinol and their optical isomers.
DELTA-3,4 CIS or their trans tetrahydrocannabinol and their optical isomers.
Synthetic Phenethylamines 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethana(25I-NBOMe/ 2C-I- NBOMe);
Enr SB 906 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe/2C-C- NBOMe);
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe/ 2C-B- NBOMe);
Synthetic Opioids (including their isomers, esters, ethers, salts and salts of isomers, esters and ethers):
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
furanyl fentanyl;
3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U- 47700);
N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide,also known as N-(1- phenethylpiperidin-4-yl)-N-phenylbutanamide, (butyryl fentanyl);
N-[1-[2-hydroxy-2-(thiophen-2-yl)ethylpiperidin-4-yl]-N-phenylpropionamide, also known as N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide(beta- hydroxythiofentanyl);
N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryl fentanyl);
N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide (isobutyryl fentanyl);
N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide (cyclopropyl fentanyl);
2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide (also known as U-48800);
Trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide (also known as U-49900);
Trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzeneacetami(also known as U-51754);
2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (butonitazene);
Enr SB 906 2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine (etodesnitazene);
N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (flunitazene);
N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine (metodesnitazene);
N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (metonitaze);
2-(4-ethoxybenzyl)5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1 H-benzimidazole (N-pyrrolidino etonitazene, etonitazepyne);
N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine (protonitazene);
N-pyrrolidino etonitazene;
Etodesnitazene;
Isotonitazene;
Protonitazene;
Metonitazene;
Butonitazene;
Metodesnitazene;
Flunitazene;
Opioid Receptor Agonist 2-Methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one) AH-7921 (3,4-dichloro-N-(1dimethylamino)cyclohexylmethyl]benzamide).
Naphthoylindoles or any compound containing a 3-(-1-Napthoyl) indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include the following:
Enr SB 906 JWH 015;
JWH 018;
JWH 019;
JWH 073;
JWH 081;
JWH 122;
JWH 200;
JWH 210;
JWH 398;
AM 2201;
and WIN 55,212.
Naphylmethylindoles or any compound containing a 1hindol-3-yl-(1-naphthyl) methane structure with a substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include, but not be limited to, JWH 175 and JWH 184.
Naphthoylpyrroles or any compound containing a 3-(1- Naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include, but not be limited to, JWH 147 and JWH 307.
Naphthylmethylindenes or any compound containing a Naphthylideneindene structure with substitution at the 3- Position of the indene ring whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent.
This shall include, but not be limited to, JWH 176.
Phenylacetylindoles or any compound containing a 3- Phenylacetylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole Enr SB 906 ring to any extent and whether or not substituted in the phenyl ring to any extent.
This shall include the following:
RCS-8, SR-18 OR BTM-8;
JWH 250;
JWH 203;
JWH 251;
and JWH 302.
Cyclohexylphenols or any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with a substitution at the 5-position of the phenolic ring whether or not substituted in the cyclohexyl ring to any extent.
This shall include the following:
CP 47,497 and its homologues and analogs;
Cannabicyclohexanol;
and CP 55,940.
Benzoylindoles or any compound containing a 3-(benzoyl) indole structure with substitution at the nitrogren atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent.
This shall include the following:
AM 694;
Pravadoline WIN 48,098;
RCS 4;
and AM 679.
[2,3-dihydro-5 methyl-3-(4-morpholinylmethyl)pyrrolo [1,2,3-DE]-1, 4-benzoxazin-6-YL]-1- napthalenymethanone.
This shall include WIN 55,212-2.
Dibenzopyrans or any compound containing a 11-hydroxydelta 8-tetrahydrocannabinol structure with substitution on the 3-pentyl group.
This shall include HU-210, HU-211, JWH 051, and JWH 133.
Enr SB 906 Adamantoylindoles or any compound containing a 3-(-1-Adamantoyl) indole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the adamantoyl ring system to any extent.
This shall include AM1248.
Tetramethylcyclopropylindoles or any compound containing A 3- tetramethylcyclopropylindole structure with substitution at the nitrogen atom of the indole ring whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent.
This shall include UR-144 and XLR-11.
N-(1-Adamantyl)-1-pentyl-1h-indazole-3-carboxamide.
This shall include AKB48.
Any other synthetic chemical compound that is a cannabinoid receptor type 1 agonist as demonstrated by binding studies and functional assays that is not listed in Schedules II, III, IV, and V, not federal Food and Drug Administration-approved drug or used within legitimate, approved medical research.
Since nomenclature of these substances is not internationally standardized, any immediate precursor or immediate derivative of these substances shall be covered.
Tryptamines:
5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT);
4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT);
5-methoxy-α-methyltryptamine (5-MeO-AMT);
4-methoxy-N,N-Dimethyltryptamine (4-MeO-DMT);
4-hydroxy Diethyltryptamine (4-HO-DET);
5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
4-acetoxy-N,N-Dimethyltryptamine (4-AcO DMT);
4-hydroxy Diethyltryptamine (4-HO-DET);
Enr SB 906 FDU-PB-22 (1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
FUB-PB-22 (Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);
5-Fluoro-MN-24 (1-(5-Fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide);
MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
Methyl-Ethylaminopentiophenone;
FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3- carboxamide);
MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3- methylbutanoat);
MN-24 (N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);
SDB-005 (Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate);
SDB-006 (1-Pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide);
Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
Methyl-Ethylaminopentiophenone;
FUB-AMB (Methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);
5-Fluoro-SDB-005 Indole (Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate);
5F-AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3- carboxamide);
MMB-CHMICA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3- methylbutanoat);
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
Enr SB 906 Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- benzodiazepin-2-one);
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);
Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2- one) ;
Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
and Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine).
(e) Depressants.
4-CN-CUMYL-BUTINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3- carboxamide);
Alpha-Phenylacetoacetonitrile (3-Oxo-2-phenylbutanenitrile);
2-Fluoro Deschloroketamine (2-(2-Fluorophenyl)-2-(methylamino)-cyclohexanone, monohydrochloride);
4-MEAP (2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one);
Mecloqualone;
Enr SB 906 Methaqualone;
Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H-[1,2,4]triazolo[4,3 a][1,4]benzodiazepine);
Cloniprazepam (5-(2-chlorophenyl)-1-(cyclopropylmethyl)-1,3-dihydro-7-nitro-2H-1,4- benzodiazepin-2-one);
Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f[1,2,4]triazolo[4,3- a][1,4]diazepine);
Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one);
Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-benzo[f][1,2,4]triazolo[4,3- a][1,4]diazepine);
gamma-hydroxybutyric acid (some other names include GHB;
gamma-hydroxybutyrate;
4-hydroxybutyrate;
4-hydroxybutanoic acid;
sodium oxybate;
sodium oxybutyrate);
Nifoxipam (5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-7-nitro-2H-1,4-benzodiazepin-2- one);
Nitrazolam (1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine);
Pyrazolam (8-bromo-1-methyl-6-(2-pyridinyl)-4H-[1,2,4]triazolo[4,3- a][1,4]benzodiazepine);
Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2- one);
and Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepine);
Enr SB 906 (f) Stimulants.
Aminorex;
some other names:
aminoxaphen;
2-amino-5- phenyl-2-oxazoline;
or 4,5- dihydro-5-phenyl-2-oxazolamine;
4,4'-Dimethylaminorex (4,4′-DMAR;
4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine;
4- methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine);
Cathinone;
some trade or other names:
2-amino-1-phenyl-1-propanone, alpha- aminopropiophenone, 2-aminopropiophenone and norephedrone;
Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);
Fenethylline;
Mesocarb (N-phenyl-N ′-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate);
Methcathinone, its immediate precursors and immediate derivatives, its salts, optical isomers and salts of optical isomers;
some other names:
(2-(methylamino)-propiophenone;
alpha- (methylamino)propiophenone;
2-(methylamino)-1-phenylpropan-1-one;
alpha- methylaminopropiophenone;
monomethylpropion;
3,4-methylenedioxypyrovalerone and/or mephedrone;3,4-methylenedioxypyrovalerone (MPVD);
ephedrone;
N-methylcathinone;
methylcathinone;
AL-464;
AL-422;
AL-463 and UR1432;
(+-) cis-4-methylaminorex;
((+-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
N-ethylamphetamine;
N,N-dimethylamphetemine;
also known as N,N-alpha-trimethyl-benzeneethanamine;
N,N-alpha-trimethylphenethylamine;
Alpha-pyrrolidinopentiophenone, also known as alpha-PVP, optical isomers, salts and salts of isomers;
Substituted amphetamines:
2-Fluoroamphetamine;
3-Fluoroamphetamine;
4-Fluoroamphetamine;
Enr SB 906 2-chloroamphetamine;
3-chloroamphetamine;
4-chloroamphetamine;
2-Fluoromethamphetamine;
3-Fluoromethamphetamine;
4-Fluoromethamphetamine;
4-chloromethamphetamine;
Ethcathinone (2-(ethylamino)-1-phenyl-1-propanone, monohydrochloride);
Alpha-PHP (1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one);
MPHP (1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one);
PV8 (1-Phenyl-2-(pyrrolidin-1-yl)heptan-1-one);
4-Chloro-Alpha-PVP (1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one);
N-Ethylhexedrone (2-(Ethylamino)-1-phenylhexan-1-one);
Methoxetamine (2-(Ethylamino)-2-(3-methoxyphenyl)-cyclohexanone);
and 3-Fluorophenmetrazine (2-(3-Fluorophenyl)-3-methylmorpholine);
(g) Temporary listing of substances subject to emergency scheduling.
Any material, compound, mixture, or preparation which contains any quantity of the following substances:
N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts, and salts of isomers;
N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanami(thenylfentanyl),its optical isomers, salts, and salts of isomers.
N-benzylpiperazine, also known as BZP;
Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
4-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]- butyramide);
Isobutyryl fentanyl (2-methyl-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-propanamide);
Enr SB 906 Methoxyacetyl fentanyl (2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]- acetamide);
3-methylbutyryl fentanyl (N-[3-methyl-1-(2-phenylethyl)piperidin-4-yl]-N- phenylbutyramide);
Show all 500 changed rows (460 more)
View plain text versions (4)
- Enrolled Enrolled Version Current pdf
- sb906 hfa burkhammer 3-13 _2 adopted.htm View text html
- sb906 h hhr am _1 adopted.htm View text html
- Introduced Introduced Version pdf
Action History
-
Filed for introduction
-
To Health and Human Resources
-
Introduced in Senate
-
To Health and Human Resources
-
Reported do pass
-
On 1st reading
-
Read 1st time
-
On 2nd reading
-
Read 2nd time
-
On 3rd reading
-
Read 3rd time
-
Passed Senate (Roll No. 260)
-
Ordered to House
-
House received Senate message
-
Introduced in House
-
To Health and Human Resources
-
To House Health and Human Resources
-
Markup Discussion
-
With amendment, do pass
-
On 1st reading, Special Calendar
-
Read 1st time
-
On 2nd reading, Special Calendar
-
Read 2nd time
-
Amendment reported by the Clerk
-
Committee amendment adopted (Voice vote)
-
Amendment reported by the Clerk
-
Amendment rejected (Voice vote)
-
On 3rd reading, Special Calendar
-
On 3rd reading, Special Calendar
-
Reported by the Clerk
-
Amendment reported by the Clerk
-
Amendment withdrawn (Voice vote)
-
Amendment reported by the Clerk
-
Amendment adopted (Voice vote)
-
Amended on 3rd reading
-
Read 3rd time
-
Passed House (Roll No. 604)
-
Communicated to Senate
-
House Message received
-
Senate concurred in House amendments and passed bill (Roll No. 660)
-
Communicated to House
-
Completed legislative action
-
To Governor 3/19/2026
-
To Governor 3/19/2026 - Senate Journal
-
Approved by Governor 3/27/2026 - House Journal
-
Approved by Governor 3/27/2026
-
Approved by Governor 3/27/2026 - Senate Journal
-
Chapter 249, Acts, Regular Session, 2026
Sponsors
- Vince Deeds · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 151 not signed on
Sponsors (1)
- Vince Deeds Republican
Co-sponsors (0)
None.
Not signed on (151)
151 members have not signed on to this bill.
Show all 151 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Votes
Roll call published as PDF — view source.
Roll call published as PDF — view source.
Roll call published as PDF — view source.
Subjects
Frequently asked questions
- What does SB 906 do?
- Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations
- Who sponsors SB 906?
- SB 906 is sponsored by Vince Deeds (Republican).
- What is the current status of SB 906?
- This bill has been enacted into law. Introduced February 10, 2026. Enacted.
- Where can I track SB 906?
- Track SB 906 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 906
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 906
Last checked for changes about 1 month ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →